Pharma Stulln GmbH

Ophthalmology

Research activity is centered on eye health, with a clear focus on myopia in children and the clinical need to slow the worsening of nearsightedness during development.

  • Myopia progression
  • Pediatric vision care
  • Refractive error

The sponsor’s clinical interest lies in ophthalmic management strategies aimed at preserving visual function in a pediatric population.

Pediatric Medicine

The funded research addresses children’s health, specifically conditions affecting visual development and the burden of early-onset vision impairment.

  • Childhood eye disorders
  • Visual development
  • Pediatric therapeutic care

This area reflects an interest in therapies relevant to younger patients, where maintaining stable eyesight is a key clinical concern.

Atropine-based ocular therapy

Clinical investigation is directed toward low-dose atropine as an eye drop treatment for controlling myopia progression.

  • Topical ophthalmic treatment
  • Atropine eye drops
  • Dose optimization

The therapeutic scope is concentrated on pharmacologic approaches within ophthalmology, with attention to treatment options suitable for routine pediatric use.

Vision preservation

The sponsor’s research interest includes interventions intended to support long-term visual outcomes by limiting the advancement of myopic refractive change.

  • Myopia control
  • Visual acuity preservation
  • Progression inhibition

These studies are situated within preventive eye care, where the aim is to reduce the clinical impact of progressive childhood myopia.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Atropine Sulfate Eye Drops to Slow Down Myopia in European Children

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Germany